Researchers discovered the elusive anti-cancer property of vitamin E that has long been presumed to exist, but difficult to find.
Many animal studies have suggested that vitamin E could prevent cancer, but human clinical trials following up on those findings have not shown the same benefits.
Researchers showed in prostate cancer cells that one form of vitamin E inhibits the activation of an enzyme that is essential for cancer cell survival. The loss of the enzyme, called Akt, led to tumour cell death. The vitamin had no negative effect on normal cells.
Chen cautioned that taking a typical vitamin E supplement won't offer this benefit for at least two reasons: The most affordable supplements are synthetic and based predominantly on a form of the vitamin that did not fight cancer as effectively in this study.
And the human body can't absorb the high doses that appear to be required to achieve the anti-cancer effect.
Chen has filed an invention disclosure with the university, and Ohio State has filed a patent application for the agent.
Vitamin E occurs in numerous forms based on their chemical structure, and the most commonly known form belongs to a variety called tocopherols.
In this study, researchers showed that, of the tocopherols tested, the gamma form of tocopherol was the most potent anti-cancer form of the vitamin.
These findings suggest that an agent based on the chemical structure of one form of vitamin E could help prevent and treat numerous types of cancer - particularly those associated with a mutation in the PTEN gene, a fairly common cancer-related genetic defect that keeps Akt active.
